[1] MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias[J]. Lancet, 1990, 335: 765-774.
[2] Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet, 2002, 360: 1903-1913.
[3] Lawes C M, Rodgers A, Bennett D A, et al. Blood pressure and cardiovascular disease in the Asia Pacific region [J]. J Hypertens, 2003, 21: 707-716.
[4] Law M R, MorrisJ K, Wald N J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. BMJ, 2009, 338: b1665.
[5] Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials[J]. Lancet, 2003, 362: 1527-1535.
[6] Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension ( ESH ) and of the European Society of Cardiology (ESC)[J].J Hypertens, 2007, 25: 1105-1187.
[7] K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease[J]. Am J Kidney Dis, 2004, 43: S1-290.
[8] Williams B, Poulter N R, Brown M J, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary[J]. BMJ, 2004 328: 634-640.
[9] Chobanian A V, Bakris G L, Black H R, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report[J]. JAMA, 2003, 289: 2560-2572.
[10] Whitworth J A. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension[J].J Hypertens, 2003, 21: 1983-1992.
[11] Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document [J]. J Hypertens, 2009, 27: 2121-2158.
[12] Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)[J]. Hypertens Res, 2009, 32: 3-107.
[13] Hypertension WgoCgftmo. 2010 Chinese guidelines for the management of hypertension[J]. Chin J Hypertens, 2011, 19: 701-743.
[14] Excellence NIfHaC (2011) Hypertension: clinical management of primary hypertension in adults. CG127[EB/OL]. http://guidanceniceorguk/CG127/Guidance/pdf/English.
[15] Arguedas J A, Perez M I, Wright J M. Treatment blood pressure targets for hypertension [J]. Cochrane Database Syst Rev , 2009, CD004349.
[16] CushmanW C, Evans G W, ByingtonR P, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med, 2010, 362: 1575-1585.
[17] Verdecchia P, Staessen J A, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension(Cardio-Sis): an open-label randomised trial[J]. Lancet, 2009, 374: 525-533.
[18] Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study [J]. Hypertension, 2010, 56: 196-202. |
